Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PROCEPT BioRobotics Corporation (PRCT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. PROCEPT BioRobotics is a surgical robotics company in urology, listed on The Nasdaq Global Market under the symbol PRCT, and its filings offer detailed information on business operations, financial performance, risk factors, and governance.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for discussions of revenue from AQUABEAM and HYDROS Robotic Systems, segment details such as U.S. and international revenue, gross margins, operating expenses, and liquidity. Current reports on Form 8-K include items such as quarterly financial results, changes to executive compensation arrangements, and other material events affecting the company.
Through this page, users can also track executive and director compensation arrangements and changes to severance or change-of-control agreements, as disclosed in 8-K exhibits. While insider transaction reports on Form 4 are not listed in the excerpts above, Stock Titan’s filings interface is designed to surface such ownership changes when available, alongside 10-K, 10-Q, and 8-K filings.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, helping readers quickly understand topics such as revenue trends, installed base growth, non-GAAP measures like Adjusted EBITDA, and risk factor highlights. Real-time updates from the SEC’s EDGAR system ensure that new PRCT filings appear promptly, allowing investors, analysts, and researchers to follow PROCEPT BioRobotics’ regulatory and financial reporting history in one place.
FMR LLCPROCEPT BioRobotics Corp. FMR LLC and Abigail P. Johnson together report beneficial ownership of 4,653,110.77 shares of PROCEPT BioRobotics common stock, representing 8.3% of the outstanding class as of the event date. FMR has sole voting power over 4,646,412 shares and sole dispositive power over 4,653,110.77 shares, while Johnson is reported with sole dispositive power over the same 4,653,110.77 shares. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
PROCEPT BioRobotics (PRCT) reported strong Q3 growth with continued losses. Revenue reached $83.3 million, up 43% year over year, driven by higher system placements, handpieces, and service. Gross margin improved to 65% from 63% as higher volumes spread fixed manufacturing costs. Net loss was $21.4 million, or $0.38 per share, compared to $21.0 million, or $0.40 per share, a year ago.
For the first nine months, revenue was $231.7 million, up 48%, with gross margin at 65%. Cash and cash equivalents were $294.3 million as of September 30, 2025, and stockholders’ equity was $380.3 million. The company had $51.6 million of long‑term debt and amended its loan in August 2025 so the entire principal is due at maturity in 2027, alongside updated cash‑holding requirements tied to balance thresholds. U.S. accounted for 89% of Q3 revenue. The installed base reached 835 AquaBeam and HYDROS robotic systems globally, including 653 in the United States. Shares outstanding were 55,878,589 as of October 29, 2025.
PROCEPT BioRobotics Corporation filed a current report stating that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company used this report to make investors aware of the new earnings release without having the detailed numbers directly in the filing.
The press release, dated November 4, 2025, is attached as Exhibit 99.1 and is incorporated by reference, but is furnished rather than filed, which limits certain legal liabilities under securities laws. The company also included a cover page interactive data file in Inline XBRL format as Exhibit 104 to support electronic reporting and data analysis.
PROCEPT BioRobotics Corporation updated its form of Change of Control and Severance Agreement for executive officers below the CEO to better align with market data. The revised form increases severance for involuntary terminations not tied to a change of control from six months to twelve months, clarifies that performance-based awards accelerated on a change of control termination will be treated as achieved at no less than target performance, and changes change-of-control cash payments to be made in a single lump sum. The company will ask eligible executives to execute amended agreements consistent with the revised form and has filed the form as Exhibit 10.1.
Larry L. Wood, President, CEO and a director of PROCEPT BioRobotics Corporation (PRCT), reported equity awards dated 09/02/2025. The filing shows an acquisition of 182,392 restricted stock units (RSUs) at $0, increasing his beneficial ownership of common stock to 185,595 shares after adjustment for the forfeiture of 2,765 unvested RSUs. The RSUs vest one-quarter on 09/02/2026 and then monthly at one-twelfth of the remaining quarterly amount thereafter, subject to continued service. The filing also discloses a stock option grant for 319,618 shares with an exercise price of $39.57, exercisable through 09/01/2036, vesting one-quarter on 09/02/2026 and then monthly thereafter. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
The filing shows that Antal Rohit Desai, a director of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 26,749 shares on 08/14/2025 at a cash exercise price of $1.33 per share. After the transaction he beneficially owns 35,152 shares in total, including 14,363 shares held indirectly by The 2:22 DNA Trust. The option exercised was fully vested and exercisable, and the exercise was executed for cash. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Desai on 08/15/2025.
Insider purchase reported: The Form 4 shows that Frederic Moll, a director of PROCEPT BioRobotics Corp (PRCT), bought 20,000 shares on 08/13/2025 at a weighted average price of $39.2569 per share. After the transactions, he beneficially owns 863,159 shares. The filing notes the shares were acquired in multiple trades with prices ranging from $38.71 to $39.645 and offers to provide a break‑down on request. The form was signed by an attorney‑in‑fact on 08/14/2025.
Nouri Alaleh, EVP and Chief Legal Officer of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 11,000 shares on 08/14/2025. The exercise was a cash exercise at an exercise price of $4.52 per share for options that are fully vested and exercisable. After the transaction the reporting person beneficially owns 72,473 shares of common stock directly and holds derivative interests corresponding to 11,000 underlying shares, with 54,452 derivative securities beneficially owned following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Procept Biorobotics (PRCT)?
What is the market cap of Procept Biorobotics (PRCT)?
